Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
blog-list-cover
Recent blog posts
Fitusiran in Hemophilia: NCT07285460 Clinical Landscape Report 2026
9 min read
Fitusiran in Hemophilia: NCT07285460 Clinical Landscape Report 2026
16 September 2026
NCT07285460 clinical landscape for Hemophilia: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
Read →
RAG-18 in Muscular Dystrophy, Duchenne: NCT07282652 Clinical Landscape Report 2026
9 min read
RAG-18 in Muscular Dystrophy, Duchenne: NCT07282652 Clinical Landscape Report 2026
16 September 2026
NCT07282652 clinical landscape for Muscular Dystrophy, Duchenne: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
Read →
Inaticabtagene Autoleucel in Neuromyelitis Optica: NCT07275736 Clinical Landscape Report 2026
9 min read
Inaticabtagene Autoleucel in Neuromyelitis Optica: NCT07275736 Clinical Landscape Report 2026
16 September 2026
NCT07275736 clinical landscape for Neuromyelitis Optica: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
Read →
Deupirfenidone in Idiopathic Pulmonary Fibrosis: NCT07284602 Clinical Landscape Report 2026
9 min read
Deupirfenidone in Idiopathic Pulmonary Fibrosis: NCT07284602 Clinical Landscape Report 2026
16 September 2026
NCT07284602 clinical landscape for Idiopathic Pulmonary Fibrosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
Read →
PIPE-791 in Idiopathic Pulmonary Fibrosis: NCT07284459 Clinical Landscape Report 2026
9 min read
PIPE-791 in Idiopathic Pulmonary Fibrosis: NCT07284459 Clinical Landscape Report 2026
16 September 2026
NCT07284459 clinical landscape for Idiopathic Pulmonary Fibrosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
Read →
Empasiprubart in Myasthenia Gravis: NCT07284420 Clinical Landscape Report 2026
9 min read
Empasiprubart in Myasthenia Gravis: NCT07284420 Clinical Landscape Report 2026
16 September 2026
NCT07284420 clinical landscape for Myasthenia Gravis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
Read →
INS-1202 in Amyotrophic Lateral Sclerosis: NCT07290062 Clinical Landscape Report 2026
9 min read
INS-1202 in Amyotrophic Lateral Sclerosis: NCT07290062 Clinical Landscape Report 2026
16 September 2026
NCT07290062 clinical landscape for Amyotrophic Lateral Sclerosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
Read →
ECC-0509 in Metabolic Dysfunction Associated Steatohepatitis: NCT07288138 Clinical Landscape Report 2026
9 min read
ECC-0509 in Metabolic Dysfunction Associated Steatohepatitis: NCT07288138 Clinical Landscape Report 2026
16 September 2026
NCT07288138 clinical landscape for Metabolic Dysfunction Associated Steatohepatitis: endpoints, sponsor, phase, geography, readouts, asset context and develo…
Read →
Tofersen in Amyotrophic Lateral Sclerosis: NCT07294144 Clinical Landscape Report 2026
9 min read
Tofersen in Amyotrophic Lateral Sclerosis: NCT07294144 Clinical Landscape Report 2026
16 September 2026
NCT07294144 clinical landscape for Amyotrophic Lateral Sclerosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
Read →
Forazapadin in Tabes Dorsalis: NCT07287189 Clinical Landscape Report 2026
9 min read
Forazapadin in Tabes Dorsalis: NCT07287189 Clinical Landscape Report 2026
16 September 2026
NCT07287189 clinical landscape for Tabes Dorsalis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
Read →
Telitacicept in Myasthenia Gravis, Ocular: NCT07298928 Clinical Landscape Report 2026
9 min read
Telitacicept in Myasthenia Gravis, Ocular: NCT07298928 Clinical Landscape Report 2026
16 September 2026
NCT07298928 clinical landscape for Myasthenia Gravis, Ocular: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
Read →
Fludarabine Phosphate in Polyradiculoneuropathy, Chronic Inflammatory Demyelinating: NCT07304154 Clinical Landscape Report 2026
9 min read
Fludarabine Phosphate in Polyradiculoneuropathy, Chronic Inflammatory Demyelinating: NCT07304154 Clinical Landscape Report 2026
16 September 2026
NCT07304154 clinical landscape for Polyradiculoneuropathy, Chronic Inflammatory Demyelinating: endpoints, sponsor, phase, geography, readouts, asset context…
Read →